Charbonneau S M, Hollins J G, Tam G K, Bryce F, Ridgeway J M, Willes R F
Toxicol Lett. 1980 Mar;5(3-4):175-82. doi: 10.1016/0378-4274(80)90056-9.
In order to assess the whole-body retention, excretion and metabolism of inorganic arsenic, male and female hamsters were given either a single oral or i.v. dose of 74As (congruent to 33' microCi/hamster; 0.01 micrograms arsenic/hamster) as arsenic acid. 74As radioactivity was measured in the whole body, urine and feces for up to 35 days. 24-h samples of urine were analyzed for arsenic metabolites. For the i.v. dosed hamsters, the half-period of elimination for the first component (65% of the dose) was 0.40 days; the second component (35% of the dose) had a half-period of 4.5 days. For the orally dosed hamsters, the half-period of elimination for the first component (98% of the dose) was 0.29 days; the second component (2% of the dose) had a half-period of 3.8 days. Differences in the percent of dose excreted between oral and i.v. dosed hamsters appeared to be due to the increased fecal excretion of arsenic (70%) in the orally dosed hamsters as compared to the i.v.v dosed hamsters (6%). No statistically significant differences between the i.v. and oral treatments were found in the half-periods of elimination for either of the 2 components. Analysis of the urine for metabolites revealed arsenic was present as dimethylarsinic acid and inorganic arsenic.
为了评估无机砷在体内的潴留、排泄及代谢情况,给雄性和雌性仓鼠经口或静脉注射一次剂量的砷酸形式的(^{74}As)(约(33)微居里/只仓鼠;(0.01)微克砷/只仓鼠)。在长达(35)天的时间里,测量了仓鼠全身、尿液和粪便中的(^{74}As)放射性。对(24)小时尿液样本进行了砷代谢产物分析。对于静脉注射给药的仓鼠,第一个成分(占剂量的(65%))的消除半衰期为(0.40)天;第二个成分(占剂量的(35%))的消除半衰期为(4.5)天。对于经口给药的仓鼠,第一个成分(占剂量的(98%))的消除半衰期为(0.29)天;第二个成分(占剂量的(2%))的消除半衰期为(3.8)天。经口给药和静脉注射给药的仓鼠之间,排泄剂量百分比的差异似乎是由于经口给药的仓鼠粪便中砷的排泄增加((70%)),而静脉注射给药的仓鼠粪便中砷的排泄为(6%)。在两种成分的消除半衰期方面,静脉注射和经口给药处理之间未发现统计学上的显著差异。对尿液代谢产物的分析表明,砷以二甲基砷酸和无机砷的形式存在。